 Terrific. Thank you very much, Martin, and thanks to my colleagues on that terrific R&D panel. And so another USAID Chamber of Commerce biosummit comes to an end. As Martin says, it feels that every year we do this, it gets better and better. It used to be this almost fringe event. And I was joking earlier that it's become the JPMorgan Conference of the East. And I think actually in some ways it has, but went up on what JPMorgan does. This was clearly a different format, not as personal in some ways, but in some ways more personal. I think the interactions amongst the panelists were really, you could feel a lot of the energy. Certainly, based on the polling question, it sounds like there's tremendous optimism amongst all of you for what's ahead for us as an industry. As we think back on the course of the day, let's pick out a few highlights. One for me, of course, is always India. This conference in the end has so little yet so much to do with India. I mean, it's an obligation that each of us have signed on for, which is to innovate and to make new medicines, but not to make new medicines for those who are privileged, but to make new medicines for everyone across the world. And there isn't a greater need in the world than for many of those impoverished in India, as we've seen represented by the horrible consequences of the COVID-19 infection. There's a second element that we touched on at various points today, which is front and center for all of us, which is diversity and inclusion. I speak for myself, but I'm guessing I speak for many of you, feel an equal obligation, not just to providing access to our great medicines to people across the world, but to enhancing diversity and inclusion in our workplaces, in our clinical trials, and the two are related. The two are related. My hope, I think all of our hope, is that the interests that we have today are coming together, and commitment around diversity and inclusion continues beyond the blip that we're seeing right now. What we're seeing right now, the social unrest, the challenges we're seeing with nationalism, this extreme right movements, it's happened before. And yet we haven't been able to keep up the endurance. It's so important that we do. I guess the last thought, and then I'll bring this to a close, is that is leadership. And we saw two great examples of leadership today, and Ken Frazier, and of course, Roy Vagelos, who hands down as the father of our industry. And if we look at a stronger ethical, we can't imagine a stronger ethical scientific leader as Roy. And equally so in Ken. Ken's not a scientist, but Ken brings that spirit of what it means to be a leader in our industry. And then I look at the two individuals, Stelios and Matai, who led and moderated those discussions equally so. And then throughout all the panels, we saw great examples of leadership in our industry. I'm just so encouraged by what's ahead. We, of course, have challenges, but I'm incredibly encouraged. And so much of that is driven by all of you. And I'd like to thank you for that. And then coming to a close, and we will end on time. Let me just say a few things. The first is, of course, reminding you again that we'll try to do this in person on June 22nd of 2021 in Cambridge. And if not, we'll figure out some way to bring this group together. We had tried after last year to create a working group to try to enhance our ability to make an impact in India. Unfortunately, with the COVID-19 pandemic, that didn't catch, that didn't really catch hold. I think now what we're finding through this COVID-19 activity and all the collaboration that's going on is that we can do this. We can come together and we can make massive impact. I'd love to see that continue. And I know that many of you would as well. So at this point, what I would do is I would say thank you to Karun. That's what I'm going to do. Karun, thank you very much. You are the spirit behind this meeting. You are a force of nature. You complimented me for never saying no. Actually, I try saying no many, many times, but you never hear no. I think, and that's what makes this so great. I might also like to thank the board of the USAIC, which is an incredibly committed group of healthcare leaders that make this event happen every year. And before I hand it over to you, Karun, I'll say that at this point, I would invite all of you out into the foyer for drinks and for a conversation. So we'll all miss the conversation, but the wine is usually mediocre at best. So I don't think we're going to miss the wine, but we certainly will miss the camaraderie and the conversation. So that's it, Karun. I'll hand it over to you to close down the... Andy, once again, thanks a lot. It wouldn't have been possible without you. So may I request all our colleagues, Chris is here, Martin, and Bill, to say something to Andy and thank him. Starting with Chris. Sorry. I'm still listening to Andy here. Okay. So there's a lag of what, 45 seconds to one minute? So, Chris. I have to say, you didn't lose anything out of doing this virtually, certainly on the content and the passion and enthusiasm that was here. Martin said it very well. And Andy, you just did a phenomenal job today. I mean, it's just even listening to your closing speech and thinking about the humanity in science, which we often forget. And I couldn't be more proud of you in doing that. And Karun, it's not easy doing this virtually, keeping everybody interested and getting everybody aligned, dealing with the sound. And you're indefatigable. You're the energizer bunny. You bring everybody together. You boss us around, and we love you for it. And so, you know, well done on that. It's just another phenomenal year. Thanks a lot. Martin. You know, I said at the beginning of the panel, Karun, you and Andy really pulled this off. And Andy's emceeing is better than I've ever seen at any of those meetings. It's simply outstanding. And as Chris said, the way that you've brought this together, Karun, with, I'm sure there's a team in the background. I'd like to thank all the AV people and the folks that, you know, coached us, gave us meetings ahead of time to make sure that it came off well. I'd like to give a profound thanks to those also about Marvelous. Thank you. Excellent. Martin, a great thought. I think the team behind us is Mass AV and Joey Chapman, who has been coordinating with you. She's a senior director, has been fantastic. Wonderful. Absolutely. I really want to thank her, you know, for, you know, looking at the details and making it happen. Bill? Well, kudos to everyone. You know, from Karun has always served the mastermind and the energy behind all of these meetings. And obviously, Andy is the now venerable emcee now many, many years in this. I think this was a tremendous, it was an extraordinary meeting. You know, I think Andy, you talked about how, in many ways, it was actually more personal, more personal. And I think we got to see faces that we probably didn't see before directly and close out. So I think this intimacy, this closeness, really, I think, the lies, really, what I think our industry, you know, might be doing. I think your last unit, Martin, really highlighted the fact that, you know, you have companies who are thinking about how we can do things better. And I think with COVID-19, it's a crisis, it's a crisis, which prevents, it's often spoken, probably incorrectly about the fact that it provides a danger, but also opportunity. And it's been an opportunity to think about how we do things differently, how we do things collaboratively, and also how we deal with, finally, the whole issue of inequity in our society, inequity of resources, economic, but also when we create all these medicines, how can we be sure that there is equitable distribution of all of these things? And I think many of these points were brought out, and I'm just so pleased, you know, I too have been involved with Karen for a little while now, and I'm overjoyed with, I won't say I have tears, but I'm overjoyed with the result today. Thank you. Thank you, Bill. Andy, there is no wine, no snacks, and there's no dinner, and then there's no toast, but the least we can do for you is at least clap for you. Thanks a lot, Andy, really. Thank you very much. Thank you. Thank you, everybody. Let's bring it to a close. Thank you, everybody. We can log off now.